Wednesday, April 25, 2012

McDonalds (MCD) Sale Thesis

McDonalds has thrived in the UASBIG portfolio, returning approximately 40% from its share price alone.  It has blown through its target price multiple times since it was added.  MCD has posted better than expected sales in recent quarters, which is not sustainable.  Since it has been doing well for so long, there is pressure to continue to beat estimates on the street.  At this point, we believe MCD has become overvalued & should be sold from our portfolio.  

Its recent growth is attributed to market share gains in the U.S. & Europe, which were driven by the McCafe line, longer hours, & an expanding breakfast menu (among other things).  But, its growth prospects should be limited in the eurozone in the coming years.  Compared to the fast-food prices in the U.S., MCD's pricing in the eurozone is more expensive compared to casual restaurants in each country.  If countries in the eurozone grow at a slow rate, MCD's sales should suffer.  Also, in its most recent conference call, CEO Jim Skinner predicted that higher commodity costs & exchange rates should hurt margins in 2012. 

Brands like KFC (YUM! Brands) should take away market share from MCD in emerging markets, especially in China.  So far, YUM! Brands has been much more successful in China than the U.S.  The ratio of KFC's to MCD in China is 10 to 1.  On Wednesday, McDonalds announced that CEO Jim Skinner will be retiring on June 30th of this year.  Donald Thompson, head of global strategy, will be replacing Jim as CEO.

From an industry-wide perspective, quick-service restaurants have been outperforming casual restaurants since the third quarter of 2009 (by comparing average same store sales).  We believe that an improving macroeconomic environment in the U.S. will cause MCD to lose some of its market share, as consumers return to less price-sensitive options for breakfast & dinner. 

We will continue to monitor MCD in the future to reassess its catalysts & potential growth.


--
As of April 9th, 2012

Alexion Pharmaceuticals (ALXN) 1Q Earnings Call


Tuesday, April 24th, ALXN announced financial results for the three months ended March 31, 2012. ALXN continues to beat Street expectations, beating revenue estimates by roughly $3 million and $0.08 in earnings. ALXN reported net sales from their revolutionary drug, Soliris, of $244.7 million, representing a 47% increase year-over-year. Revenue performance is a reflection of added PNH patients in the U.S., Western Europe, Japan and in other countries, augmented by a steady increase in new patients from the aHUS indication. GAAP net income also increased 69% to $45.4 million or simply $0.23 per share, compared to $26.8 million and $0.29 year-over-year. Furthermore, ALXN recognized $359 million in cash compared to $541 million at year end 2011. This change reflects positive cash flow from operations during the quarter and acquisition-related debt, offset by the outflows from the Enobia purchase. In addition, GAAP operating expenses increased to $146.4 million, compared to $106.7 million year-over-year, primarily due to an increase in R&D, SG&A, and acquisition-related expenses. Management also gave optimistic forecasting by increasing and narrowing 2012 revenue guidance, previously in the range of $1.04-1.07 billion to $1.065-1.085 billion. With this increased forecast, combined with the control of expenses within previously guided ranges, ALXN is also raising non-GAAP earnings from the range of $1.60-1.70 to a higher range of $1.65-1.75.  However, despite positive earnings, the stock dipped due to the lack of expected quantitative results and forecasts on the developing pipeline. That being said, ALXN’s annual shareholder meeting is set for May, 7th, where additional insight is anticipated to be visible.

Alexion Pharmaceuticals (ALXN) 1Q Earnings Call


Tuesday, April 24th, ALXN announced financial results for the three months ended March 31, 2012. ALXN continues to beat Street expectations, beating revenue estimates by roughly $3 million and $0.08 in earnings. ALXN reported net sales from their revolutionary drug, Soliris, of $244.7 million, representing a 47% increase year-over-year. Revenue performance is a reflection of added PNH patients in the U.S., Western Europe, Japan and in other countries, augmented by a steady increase in new patients from the aHUS indication. GAAP net income also increased 69% to $45.4 million or simply $0.23 per share, compared to $26.8 million and $0.29 year-over-year. Furthermore, ALXN recognized $359 million in cash compared to $541 million at year end 2011. This change reflects positive cash flow from operations during the quarter and acquisition-related debt, offset by the outflows from the Enobia purchase. In addition, GAAP operating expenses increased to $146.4 million, compared to $106.7 million year-over-year, primarily due to an increase in R&D, SG&A, and acquisition-related expenses. Management also gave optimistic forecasting by increasing and narrowing 2012 revenue guidance, previously in the range of $1.04-1.07 billion to $1.065-1.085 billion. With this increased forecast, combined with the control of expenses within previously guided ranges, ALXN is also raising non-GAAP earnings from the range of $1.60-1.70 to a higher range of $1.65-1.75.  However, despite positive earnings, the stock dipped due to the lack of expected quantitative results and forecasts on the developing pipeline. That being said, ALXN’s annual shareholder meeting is set for May, 7th, where additional insight is anticipated to be visible. 

-Shawn Laljit

Alexion Pharmaceuticals (ALXN) 1Q Earnings Call


Tuesday, April 24th, ALXN announced financial results for the three months ended March 31, 2012. ALXN continues to beat Street expectations, beating revenue estimates by roughly $3 million and $0.08 in earnings. ALXN reported net sales from their revolutionary drug, Soliris, of $244.7 million, representing a 47% increase year-over-year. Revenue performance is a reflection of added PNH patients in the U.S., Western Europe, Japan and in other countries, augmented by a steady increase in new patients from the aHUS indication. GAAP net income also increased 69% to $45.4 million or simply $0.23 per share, compared to $26.8 million and $0.29 year-over-year. Furthermore, ALXN recognized $359 million in cash compared to $541 million at year end 2011. This change reflects positive cash flow from operations during the quarter and acquisition-related debt, offset by the outflows from the Enobia purchase. In addition, GAAP operating expenses increased to $146.4 million, compared to $106.7 million year-over-year, primarily due to an increase in R&D, SG&A, and acquisition-related expenses. Management also gave optimistic forecasting by increasing and narrowing 2012 revenue guidance, previously in the range of $1.04-1.07 billion to $1.065-1.085 billion. With this increased forecast, combined with the control of expenses within previously guided ranges, ALXN is also raising non-GAAP earnings from the range of $1.60-1.70 to a higher range of $1.65-1.75.  However, despite positive earnings, the stock dipped due to the lack of expected quantitative results and forecasts on the developing pipeline. That being said, ALXN’s annual shareholder meeting is set for May, 7th, where additional insight is anticipated to be visible.

-Shawn Laljit

Tuesday, April 24, 2012

Parker Reports Q3 Earnings

Parker-Hannifin (Ticker: PH) reported record sales, EPS, and Net Income for the Third Quarter for Fiscal 2012. Sales Reached $3.4 Billion, 4.7% over last year's previous record, while Net Income tallied 312.7, an increase of 11% when compared to last year's Q3, and EPS reached $2.01 per share, a 19% increase over last year, and proof that Washkewicz has been able to further implement his strategy to cut down SG&A to lead to stronger margins, with total segment operating margins totally 15.1%, a company record. Cash Flow from Operations was $1.006 Billion, or 10.3% of sales, compared to last year's mark of 9%. There was serious discussion about future growth prospects as management changed FY2012 EPS to $7.50 per share from $7.30.  The Company also increased their dividends to $.41, a 5% increase over the previous quarter. The market has reacted well pre-market with shares trading up 2%.

Matthew Buechele

Monday, April 23, 2012

BSX F1Q12 Earnings 04/19/12 - (Ryan Kennedy)

Boston Scientific reported Q1 earnings for the period ending March 31st on April 19th. Throughout the day, shares of BSX traded up 5.8% on EPS results that exceeded management guidance and analyst expectations. BSX reported GAAP EPS of $0.08 and adjusted EPS of $0.15, which exceeded analyst expectations of $0.10. Earnings doubled from the previous period from continued cost cutting and a decrease in restructuring charges. Despite strong earnings, the company reported $1.87 billion in revenues, down $60 million from the previous period, and under performed analyst expectations of $1.90 billion.

Although BSX missed revenue estimates, the company saw positive developments in the cardiac rhythm management (CRM) business, which accounts for 27% of the firm's revenues. The CRM market had been slowing, with Q4 CRM sales dropping 15%. This quarter CRM sales dropped 5%, which was better than expected, and management believes this may be the end of the fall in CRM sales. Additionally, Boston Scientific saw positive developments with the PROMUS Element Platinum stent system, which is key to UASBIG's investment thesis. Clinical trials showed the Element's superior efficacy to both the previous PROMUS offering and Abbott Laboratories' Xience V stent system. The Element stent system has been approved in both Europe and U.S. markets, and should begin to boost the interventional cardiology business this fiscal year. The firm also saw developments in the CRM unit with the release of the INGENIO pacemaker system in Europe.

Going forward, we expect to see an increase in top line revenues driven by the PROMUS Element stent system and a rebound in the CRM division. Additionally, gross margins are expected to increase as the company shifts from marketing the original PROMUS system to the Element system, which commands twice the margins of the previous offering. For the next fiscal quarter, management expects sales of $1.95 billion and adjusted EPS of $0.17.

-Ryan M. Kennedy

Sunday, April 22, 2012

BlackRock Reports Q1 Earnings

BlackRock, Inc. reported first quarter earnings per share of $3.16 beating the estimates of coverage analysts by $0.12. Assets under management grew by 5% from the previous quarter, to $3.684 Trillion. Revenue was in line with estimates, down 1% from a year earlier. BlackRock saw strong inflows in the areas of iShares – Exchange Traded Products, multi-asset class and alternatives. As asset classes gain momentum BlackRock remains well positioned to take advantage of asset inflows.
During the quarterly conference call, BlackRock noted that investors recognize the large amount of uncertainty in the investment environment that lies ahead.  Upcoming elections in the U.S. and France as well as sovereign debt issues in Europe are just a few examples.  As these tensions ease investors will move back into long-term investments with renewed confidence. During the first quarter BlackRock began a large marketing campaign with the goal of building the brand and the sediment that investors should look at investing on a longer time line.
Our expectations are that BlackRock will continue to build innovative financial products and create asset inflows. With a strong brand image in place we are confident BlackRock has all of the necessary mechanisms in place to have a strong second quarter.
-George Hoffmann